Regulus Therapeutics Inc (NASDAQ:RGLS)’s share price was down 19.9% during trading on Friday . The company traded as low as $1.17 and last traded at $1.17. Approximately 576,084 shares traded hands during trading, an increase of 69% from the average daily volume of 340,945 shares. The stock had previously closed at $1.46.
RGLS has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 11th. Wedbush set a $2.00 price objective on shares of Regulus Therapeutics and gave the company a “hold” rating in a report on Friday, January 25th. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. The company currently has an average rating of “Hold” and an average price target of $1.38.
The firm has a market cap of $11.38 million, a price-to-earnings ratio of -0.10 and a beta of 2.26.
In related news, Director Stelios Papadopoulos acquired 50,000 shares of the firm’s stock in a transaction that occurred on Friday, December 28th. The stock was bought at an average price of $1.09 per share, for a total transaction of $54,500.00. Following the acquisition, the director now directly owns 835,073 shares of the company’s stock, valued at approximately $910,229.57. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.40% of the company’s stock.
A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC grew its holdings in Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the quarter. Renaissance Technologies LLC owned approximately 6.82% of Regulus Therapeutics worth $118,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 46.22% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Regulus Therapeutics (RGLS) Shares Down 19.9%” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://transcriptdaily.com/2019/03/16/regulus-therapeutics-rgls-shares-down-19-9.html.
About Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Article: Buyback
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.